Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38

Benzinga · 1d ago
Oppenheimer analyst Jay Olson maintains Sagimet Biosciences (NASDAQ:SGMT) with a Outperform and raises the price target from $33 to $38.